NASDAQ:FENC

Fennec Pharmaceuticals Stock Forecast, Price & News

$7.71

+0.05 (+0.65 %)

(As of 10/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$7.67

Now: $7.71▼

$7.78

50-Day Range

$5.19

MA: $6.41▼

$8.09

52-Week Range

$4.60

Now: $7.71▼

$10.67

Volume64,267 shs

Average Volume228,614 shs

Market Capitalization$199.00 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.11

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Fennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.67, Fennec Pharmaceuticals has a forecasted upside of 90.2% from its current price of $7.71.
Amount of Analyst Coverage
Fennec Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Fennec Pharmaceuticals has received 163 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Fennec Pharmaceuticals has received 168 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Fennec Pharmaceuticals has received 50.76% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote “Outperform” if you believe FENC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Fennec Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Fennec Pharmaceuticals does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fennec Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.08% of the stock of Fennec Pharmaceuticals is held by insiders.
Percentage Held by Institutions
55.23% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Fennec Pharmaceuticals are expected to grow in the coming year, from ($0.80) to $1.20 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fennec Pharmaceuticals is -11.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fennec Pharmaceuticals is -11.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fennec Pharmaceuticals has a P/B Ratio of 12.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:FENC

Previous Symbol

CUSIPN/A

CIK1211583

Webwww.fennecpharma.com

Phone919-636-4530

EmployeesN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio12.19

Quick Ratio12.19

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.60 per share

Price / Book12.85

Profitability

EPS (Most Recent Fiscal Year)($0.64)

Net Income$-12,770,000.00

Net MarginsN/A

Return on Equity-78.86%

Return on Assets-70.68%

Miscellaneous

Outstanding Shares25,810,000

Market Cap$199.00 million

Next Earnings Date11/10/2020 (Estimated)

OptionableOptionable

$7.71

+0.05 (+0.65 %)

(As of 10/23/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.

Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

How has Fennec Pharmaceuticals' stock price been impacted by Coronavirus?

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FENC stock has increased by 16.3% and is now trading at $7.71.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Fennec Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fennec Pharmaceuticals.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Fennec Pharmaceuticals.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.03.
View Fennec Pharmaceuticals' earnings history.

What price target have analysts set for FENC?

3 Wall Street analysts have issued 1 year price objectives for Fennec Pharmaceuticals' shares. Their forecasts range from $11.00 to $18.00. On average, they expect Fennec Pharmaceuticals' stock price to reach $14.67 in the next year. This suggests a possible upside of 90.2% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals.

Are investors shorting Fennec Pharmaceuticals?

Fennec Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,380,000 shares, an increase of 16.9% from the August 31st total of 1,180,000 shares. Based on an average daily trading volume, of 470,400 shares, the days-to-cover ratio is currently 2.9 days. Currently, 7.3% of the company's stock are short sold.
View Fennec Pharmaceuticals' Short Interest.

Who are some of Fennec Pharmaceuticals' key competitors?

Some companies that are related to Fennec Pharmaceuticals include Passage Bio (PASG), Alector (ALEC), Agenus (AGEN), Taysha Gene Therapies (TSHA), Inhibrx (INBX), Tcr2 Therapeutics (TCRR), Poseida Therapeutics (PSTX), Osiris Therapeutics (OSIR), BioCryst Pharmaceuticals (BCRX), Adaptimmune Therapeutics (ADAP), CEL-SCI (CVM), Vaxart (VXRT), AVROBIO (AVRO), Oyster Point Pharma (OYST) and Autolus Therapeutics (AUTL).
View all competitors.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus Biosciences (CHRS) and Exelixis (EXEL).

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:

Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
Mr. Mark Gowland, Controller
Mr. Lei Fang, Pres of Pharstat Inc
Ms. Anne McKay, Regulatory Consultant (Age 64)

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.27%), Hartford Financial Management Inc. (0.15%) and Cadence Capital Management LLC (0.14%).
View institutional ownership trends for Fennec Pharmaceuticals.

Which institutional investors are selling Fennec Pharmaceuticals stock?

FENC stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, and Hartford Financial Management Inc..
View insider buying and selling activity for Fennec Pharmaceuticals.

Which institutional investors are buying Fennec Pharmaceuticals stock?

FENC stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
View insider buying and selling activity for Fennec Pharmaceuticals.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $7.71.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of $199.00 million. The company earns $-12,770,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.

This page was last updated on 10/25/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings